T3 Pharma Overview

  • Founded
  • 2015
  • Status
  • Private
  • Employees
  • 11
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $26.5M
Latest Deal Amount
  • Investors
  • 9

T3 Pharma General Information


Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary protein delivery platform by repurposing the bacterial type III secretion (T3S) system to treat solid cancer tumors, enabling healthcare providers to improve the lives of the patients and cure them.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • C/o Biozentrum, Universität Basel
  • Klingelbergstr. 50/70
  • 4056 Basel
  • Switzerland
+41 061 000 00 00

T3 Pharma Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

T3 Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 22-Jul-2020 $26.5M 000.00 Completed Generating Revenue
5. Early Stage VC 26-Sep-2019 000.00 000.00 000.00 Completed Generating Revenue
4. Grant 28-May-2019 000.00 00.000 Completed Generating Revenue
3. Accelerator/Incubator 30-Jan-2018 00000 00.000 Completed Generating Revenue
2. Angel (individual) 28-Nov-2016 $2.91M $2.91M Completed Pre-Clinical Trials
1. Grant $2.01M Completed Pre-Clinical Trials
To view T3 Pharma’s complete valuation and funding history, request access »

T3 Pharma Executive Team (5)

Name Title Board Seat Contact Info
Simon Ittig Ph.D Co-Founder & Chief Executive Officer
Christoph Kasper Ph.D Co-Founder & Chief Scientific Officer
Marlise Amstutz Ph.D Co-Founder & Executive Director
Helmut Kessmann Ph.D Co-Founder & Board Member
Claire Barton Chief Medical Officer
To view T3 Pharma’s complete executive team members history, request access »

T3 Pharma Board Members (3)

Name Representing Role Since
Frank Kalkbrenner MD Boehringer Ingelheim Venture Fund Board Member 000 0000
Helmut Kessmann Ph.D T3 Pharma Co-Founder & Board Member 000 0000
Olvier Valdenaire Ph.D Self Chairman 000 0000
To view T3 Pharma’s complete board members history, request access »

T3 Pharma Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

T3 Pharma Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Wille Finance Family Office Minority 000 0000 000000 0
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
Reference Capital (Switzerland) Venture Capital Minority 000 0000 000000 0
W A de Vigier Foundation Other 000 0000 000000 0
BaseLaunch Healthcare Accelerator Accelerator/Incubator 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »